FTC Finalizes Changes to Premerger Notification Form: What It Means for Healthcare Transactions


At long last, we have a rule. On October 10, 2024, the Federal Trade Commission (FTC) unanimously issued a final rule updating the Hart-Scott-Rodino Act (HSR Act) premerger notification process (the Final Rule). The Final Rule is expected to go into effect in January 2025. While the Final Rule is less burdensome than the FTC’s initial 2023 proposal, it nonetheless implements the most sweeping reforms to the premerger notification process in the nearly 50 years since the HSR Act’s enactment. These reforms will be felt across a wide range of industries, particularly so in healthcare.

The Final Rule

The Final Rule seeks to address what the FTC describes as “gaps” in the current HSR framework that have led to inadequate enforcement, such as (1) disclosure of entities and individuals within the acquiring person; (2) identification of potential labor market effects; (3) identification of acquisitions that create a risk of foreclosure; (4) identification of potential law violations involving innovation effects, future market entry, or nascent competitive threats; and (5) disclosure of roll-up or serial acquisition strategies.

To address these perceived gaps, the Final Rule requires parties to a reportable transaction to provide more extensive data and information across a variety of categories. The most significant changes include:

The Final Rule will also require the acquiring person to disclose recent officers and directors who have responsibility for the development, marketing, or sale of any products or services in overlapping revenue categories. The acquiring person must identify the board and corporate affiliations that each officer and director holds with other entities outside of the filing company, where those entities are in the same industry as the target.

The Final Rule further requires “that acquiring persons provide a description of the ownership structure of the acquiring entity and, for fund or master or master limited partnership UPEs, an organizational chart sufficient to identify and show the relationship of all the entities that are affiliates or associates … if such charts exist.”

While the June 2023 Notice of Proposed Rulemaking would have required disclosure of detailed information about employees and competition for labor, the Final Rule has eliminated this requirement. The Final Rule does not require the parties to provide detailed information regarding competition for employees, including noncompete, or non-solicitation agreements; however, the Final Rule expressly notes that the FTC might still require such information pursuant to a Request for Additional Documentary Information and Materials (“Second Request").

The Final Rule also preserves the ability for parties to file on the basis of a letter of intent (LOI) or memorandum of understanding (MOU), provided that the LOI or MOU contains sufficient details regarding “the identity of the parties; the structure of the transaction; the scope of what is being acquired; calculation of the purchase price; an estimated closing timeline; employee retention policies, including with respect to key personnel; post-closing governance; and transaction expenses or other material terms” (see final rule at 82).

In conjunction with the Final Rule, the FTC has also announced a new electronic portal for market participants, stakeholders, and the general public to weigh in directly and submit comments on proposed transactions that may be under review by the FTC. The FTC is specifically seeking the perspectives of “consumers, workers, suppliers, rivals, business partners, advocacy organizations, professional and trade associations, local, state, and federal elected officials, academics, and others.” Comments provided through the portal will be publicly available, while filing parties’ HSR forms and other information provided pursuant to the HSR Act remains confidential and exempt from Freedom of Information Act requests.

Looking Ahead

The Final Rule is consistent with the FTC’s recent initiatives to strengthen merger control. Specific to the healthcare industry, the agency relied on its “significant expertise and interest in preventing hospital mergers that may violate the antitrust laws” in tailoring the Final Rule to address those healthcare transactions “that are most likely to present antitrust risk” (see final rule at 171). Moreover, the Final Rule identifies the healthcare industry as one in which serial acquisition strategies (e.g., “roll-ups”) are particularly prevalent, and even more so in healthcare markets involving private equity buyers. Healthcare entities that engage in large transactions – particularly those involving hospitals – should be prepared for an onerous premerger process delving into their organizational structure, finances, and recent acquisition history, while also keeping an eye towards a potential Second Request. Indeed, the FTC has estimated that the Final Rule will require an average of 68 additional hours to comply with the changes, with certain transactions involving overlaps or supply relationships taking up to 121 additional hours of preparation (see final rule at 379-80).


© 2025 Bradley Arant Boult Cummings LLP
National Law Review, Volume XIV, Number 292